Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001309-95
    Sponsor's Protocol Code Number:MPH966-2-01
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:GB - no longer in EU/EEA
    Date on which this record was first entered in the EudraCT database:2018-07-31
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2018-001309-95
    A.3Full title of the trial
    A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks twice daily oral administration of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiency.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 2 placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of alvelestat (MPH966) in participants with alpha-1 antitrypsin deficiency
    A.4.1Sponsor's protocol code numberMPH966-2-01
    A.5.4Other Identifiers
    Name:INDNumber:101534
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMereo BioPharma 4 Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMereo BioPharma Group Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMereo BioPharma 4 Ltd
    B.5.2Functional name of contact pointClinical Operations Department
    B.5.3 Address:
    B.5.3.1Street Address1 Cavendish Place
    B.5.3.2Town/ cityLondon
    B.5.3.3Post codeW1G 0QF
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number4403330237300
    B.5.5Fax number4403330237301
    B.5.6E-mailenquiries@mereobiopharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAlvelestat
    D.3.2Product code MPH966
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAlvelestat tosylate
    D.3.9.1CAS number 1240425-05-1
    D.3.9.2Current sponsor codeMPH966
    D.3.9.3Other descriptive nameALVELESTAT
    D.3.9.4EV Substance CodeSUB130609
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Alpha-1 antitrypsin deficiency
    E.1.1.1Medical condition in easily understood language
    Alpha-1 antitrypsin deficiency is a genetic disorder that may result in lung disease or liver disease.
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10001806
    E.1.2Term Alpha-1 anti-trypsin deficiency
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the mechanistic effect of alvelestat (MPH966) administered bid for 12 weeks on blood markers of neutrophil elastase activity
    E.2.2Secondary objectives of the trial
    Secondary objectives:
    • To evaluate the effect of alvelestat (MPH966) on other blood pharmacodynamic markers of neutrophil activation and elastase activity
    • To evaluate the effect of alvelestat (MPH966) on blood biomarkers of lung tissue degradation
    • To evaluate the effect of alvelestat (MPH966) on biomarkers of inflammation in blood
    • To evaluate the safety and tolerability of alvelestat (MPH966) administered bid for 12 weeks
    Exploratory
    • To evaluate the effect of alvelestat (MPH966) on other blood PD markers of neutrophil activation and elastase activity
    • To evaluate the effect of alvelestat (MPH966) on pulmonary function
    • To evaluate the effect of alvelestat (MPH966) on respiratory symptoms
    • To evaluate the effects of alvelestat on acute exacerbations of COPD
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Sputum will either be induced or spontaneously produced by participants.
    • Sputum will be collected from all participants that spontaneously produce sputum according to the MPH966-2-01 Study Procedures Manual.
    • Participants who do not spontaneously produce sputum will be invited to participate in the induced sputum subset study. The aim to meet the study objectives is to include approximately 30% to 50% of non-sputum producers in the subset study. Sputum induction will not be undertaken if the baseline FEV1 for the procedure is less than 1 L. Further details of sputum induction will be included in the MPH966-2-01 Study Procedures Manual.
    E.3Principal inclusion criteria
    1. Age 18 to 75 years at screening
    2.Participants with a diagnosis or confirmation of AATD (PiZZ or, null or other rare phenotype/genotype) with an associated serum AAT levelslevel of <11 µM or <57.2 mg/dL
    3.Post-bronchodilator FEV1≥20% predicted at screening
    4.Computerised tomography (CT) scan evidence of emphysema
    5.Non-smokers (for at least 12 months prior to study entry)
    6.Absence of advanced liver fibrosis or cirrhosis:
    a.Fibrosis-4 (FIB-4) score <1.45 or
    b.FIB-4 score >1.45 and ≤3.25 with transient elastography measurement <12.5 kPa within 3 months of baseline
    7.Male or female
    Male participants: A male participant must agree to use a highly effective contraception as detailed in Appendix 5 during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period
    Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix 5), not breastfeeding, and at least 1 of the following conditions applies:
    a.Not a woman of childbearing potential as defined in Appendix 5 OR
    b.A woman of childbearing potential who agrees to follow the contraceptive guidance in Appendix 5 during the treatment period and for at least 4 days after the last dose of study treatment
    8.Capable of giving signed informed consent as described in Appendix 3, which includes a commitment to comply with the requirements and restrictions listed in the informed consent form (ICF) and within this protocol
    E.4Principal exclusion criteria
    1. Participants with PiMZ, PiFF or PiSZ AATD phenotypes/genotypes
    2. Primary clinical diagnosis of bronchiectasis or evidence of significant bronchiectasis on CT scan Acute exacerbation of underlying lung disease requiring oral corticosteroids, antibiotics, and/or change in regular treatments within 4 weeks of baseline
    3. Acute exacerbation of underlying lung disease requiring oral corticosteroids, antibiotics, and/or change in regular treatments within 4 weeks of baseline
    4. Acute or chronic hepatitis, including hepatitis B and or C virus infection (positive hepatitis B surface antigen, and /or hepatitis C antibody) at screening
    5. Known history or present diagnosis of cirrhosis (on imaging or biopsy), oesophageal varices, ascites or hepatic encephalopathy
    6. History of other chronic liver diseases such as autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson’s disease, haemochromatosis
    7. History of non-alcoholic fatty liver disease
    8. A clinical requirement for drugs associated with NAFL or hepatoxicity during the study period (Screening through Week 12 Visit) and up to 4 weeks prior to screening.
    9. History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening, defined as an average of >20 g / day in female subjects and >30 g/ day in male subjects
    10. History of alcohol and/or drug abuse within the 15 years prior to screening
    11. HIV infection OR known other immunodeficiency OR an absolute neutrophil count ≤1.0 × 109/L at screening
    12. Any of the following lab abnormalities suggestive of liver disease: abnormal liver-related biochemistry at screening >1.5 × upper limit of normal OR gamma-glutamyl transferase >2 × upper limit of normal OR total bilirubin > upper limit of normal (unless Gilbert’s disease with normal conjugated bilirubin), platelet count <150 x 109/L, serum albumin ≤ 3.5g/dL or INR ≥1.2 (in the absence of drugs known to elevate INR, for example anticoagulant therapy) or CPK > 1.5 x ULN
    13. FIB-4 score >3.25 at screening
    14. Any of the following cardiovascular conditions within 6 months prior to the screening visit:
    a. Myocardial infarction or unstable angina
    b. Stroke or transient ischaemic attack
    c. Coronary artery bypass surgery, balloon angioplasty, percutaneous coronary intervention, or carotid revascularisation procedure
    d. Uncontrolled hypertension within the 3 months prior to screening
    e. Congestive heart failure
    15. Any clinically significant 12-lead electrocardiogram abnormalities at screening or baseline OR corrected QT interval by Fridericia’s correction method >450 ms OR history of significant cardia dysrhythmia, including long QT syndrome
    16. Significant renal disease or infection (as determined by the Investigator) including stage 4 chronic kidney disease or estimated glomerular filtration rate <45 mL/min
    17. History of cancer within the 5 years prior to screening, except for well-treated cutaneous basal cell carcinoma, squamous cell carcinoma of the skin and cervical cancer
    18. Other clinically relevant haematology parameters that could impact the safety of the participant in the Investigator’s judgement
    19. Other documented comorbidities that in the opinion of the Investigator could affect the outcome of the study assessments or ability of the participant to comply with the requirements of the protocol
    20. Lung or lung volume reduction surgery or liver transplant has been performed or the participant is listed and active on a transplant waiting list
    21. Immunosuppressive therapies including regular systemic corticosteroids (>5 mg daily or equivalent for greater than 14 consecutive days) within 4 weeks prior to screening
    22. Immunomodulating monoclonal antibodies within the 6 months prior to screening
    23. Previous AAT augmentation therapy within the 6 months prior to screening
    24. Requirement for non-steroidal anti-inflammatory drugs (however, paracetamol [acetaminophen] up to 2 g per day and up to 100 mg acetylsalicylic acid daily is allowed)
    25. Requirement for medications mainly metabolised by CYP2C9 and with a narrow therapeutic index
    26. Requirement for medications substantially reliant on OATP1B1 for metabolism (e.g., statins, valsartan, olmesartan, enalapril, repaglinide)
    27. Commenced treatment with PDE4 inhibitor or regular azithromycin within 4 weeks of screening (stable therapy for greater than 4 weeks is acceptable)
    28. Participation in any clinical investigation using medical devices or non-biologic treatments within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the initial dosing
    29. Participation in any clinical investigation using biologic treatment within 6 months of screening
    30. Previous participation in a gene therapy study for AATD at any time
    31. History of hypersensitivity to alvelestat (MPH966) or any of its excipients or the class of neutrophil elastase inhibitors.
    E.5 End points
    E.5.1Primary end point(s)
    Within-individual % change from baseline in plasma desmosine/isodesmosine at end of treatment compared to placebo
    E.5.1.1Timepoint(s) of evaluation of this end point
    Blood sample for desmosine/isodesmosine: Base, W4, W8, W12 (EOT) and W16 (Safety FU visit)
    E.5.2Secondary end point(s)
    • Change from baseline in absolute plasma desmosine/isodesmosine levels at end of treatment compared to placebo
    • Change from baseline in blood Aα-Val360, neutrophil elastase, EL-NE, EL-CG, and EP-3 at end of treatment compared to placebo
    • Change from baseline in blood MMP: C6M, Pro-C6, C1M, and PGP at end of treatment compared to placebo
    • Change from baseline in blood inflammatory biomarkers (interleukin [IL]-6, IL-8, IL-1β, RANTES, high-sensitivity C-reactive protein, fibrinogen) at end of treatment compared to placebo
    • Numbers and % of participants who experience at least 1 treatment-emergent adverse event
    • Adverse events of special interest (liver function abnormalities, corrected QT interval/cardiac, infections, and neutropenia)
    • Relationship of pharmacokinetics (PK) and safety
    Exploratory
    • Change from baseline in markers of neutrophil elastase activity, desmosine, and inflammatory biomarkers (IL-6, IL-8, IL-1β, LTB4, RANTES, PGP) at end of treatment in induced sputum compared to placebo
    • Change from baseline in markers of neutrophil elastase activity, desmosine, and inflammatory biomarkers (IL-6, IL-8, IL-1β, LTB4, RANTES, PGP) at end of treatment in spontaneous sputum compared to placebo
    • Change from baseline in forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC (total and percent predicted), and maximal mid-expiratory flow at end of treatment
    • Change from baseline in St. George’s Respiratory Questionnaire (SGRQ-C) at end of treatment
    • Frequency of adverse events of acute exacerbations of COPD, at 12 weeks
    • PK/pharmacodynamic (PD) relationship with efficacy biomarkers in blood and sputum
    E.5.2.1Timepoint(s) of evaluation of this end point
    Blood sample for PD BK and PK: Alvelestat PK; IL-6, IL-8, IL-1β, RANTES, hsCRP, fibrinogen; desmosine/isodesmosine, neutrophil elastase; Aα-Val360; PGP; neutrophil elastase, EL-NE, EL-CG, EP-3, C6M, C1M, PRO-C6: Base, W4, W8, W12 (EOT) + W16 (Safety FU visit) for desmosine/isodesmosine, neutrophil elastase and Aα-Val360

    Sputum collection for biomarkers of desmosine, neutrophil elastase and inflammation RANTES, IL-1β, IL-6, IL-8, LTB4, PGP: Base, W4, W8, W12 (EOT). For induced sputum collection: Screening, baseline, W8, W12 (EOT)

    Lung function tests (FEV1, FVC, FEV1/FVC, maximal mid-expiratory flow): Base, W4, W8, W12 (EOT)
    12-Lead ECG: Baseline, W4, W8, W12 (EOT)

    Clinical laboratory tests: Scr, Base, W-1, W2, W4, W8, W12, Safety FU visit

    SGRQ-C: Base, W4, W8, W12 (EOT)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Mechanistic effect
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA18
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    Denmark
    Poland
    Spain
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of all data being entered into the study database and the database being locked and ready for analysis.

    Mereo BioPharma 4 Ltd (sponsor) considers that the trial is ended when the clinical database is locked and all data is ready for analysis, which should occur within 1 month after the last patient last visit.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months18
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 127
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 55
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state55
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 117
    F.4.2.2In the whole clinical trial 182
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-09-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-11-30
    P. End of Trial
    P.End of Trial StatusGB - no longer in EU/EEA
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 27 04:47:24 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA